A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer

Effectiveness Analysis ◽

220P A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer

Annals of Oncology ◽

10.1016/j.annonc.2020.10.440 ◽

2020 ◽

Vol 31 ◽

pp. S1326

Author(s):

W.W. Sung ◽

H.C. Choi ◽

P.H. Luk ◽

T.H. So

Keyword(s):

Prostate Cancer ◽

Cost Effectiveness ◽

Systemic Therapy ◽

Effectiveness Analysis ◽

Cost-effectiveness analysis of innovative therapy for patients with newly diagnosed hormone-sensitive metastatic prostate cancer

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2021.03.022 ◽

2021 ◽

Author(s):

Rémi Pelloux-Prayer ◽

Philomène Schiele ◽

Stéphane Oudard ◽

Gwenaëlle Gravis ◽

François Kleinclauss ◽

...

Keyword(s):

Prostate Cancer ◽

Cost Effectiveness ◽

Metastatic Prostate Cancer ◽

Newly Diagnosed ◽

Innovative Therapy ◽

Effectiveness Analysis ◽

Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer

Einstein (São Paulo) ◽

10.31744/einstein_journal/2019gs4414 ◽

2019 ◽

Vol 17 (2) ◽

Cited By ~ 1

Author(s):

Pedro Nazareth Aguiar ◽

Pui San Tan ◽

Sarah Simko ◽

Carmelia Maria Noia Barreto ◽

Bárbara de Souza Gutierres ◽

...

Keyword(s):

Prostate Cancer ◽

Cost Effectiveness ◽

Advanced Prostate Cancer ◽

Androgen Deprivation ◽

Effectiveness Analysis ◽

Cost-effectiveness analysis of additional docetaxel for metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy from a Chinese perspective

European Journal of Cancer Care ◽

10.1111/ecc.12505 ◽

2016 ◽

Vol 26 (6) ◽

pp. e12505 ◽

Cited By ~ 5

Author(s):

H.R. Zheng ◽

F. Wen ◽

Y.F. Wu ◽

J.R.C. Wheeler ◽

Q. Li

Keyword(s):

Prostate Cancer ◽

Cost Effectiveness ◽

Androgen Deprivation ◽

Effectiveness Analysis ◽

Chinese Perspective ◽

01 / COST-EFFECTIVENESS ANALYSIS OF AN EXERCISE INTERVENTION TARGETING PHYSICAL FUNCTIONING IN LONG TERM SURVIVORS OF PROSTATE CANCER PREVIOUSLY TREATED WITH ANDROGEN DEPRIVATION THERAPY

10.26226/morressier.5afadd8af314ac000849b335 ◽

2018 ◽

Author(s):

Kim Edmunds

Keyword(s):

Prostate Cancer ◽

Cost Effectiveness ◽

Physical Functioning ◽

Exercise Intervention ◽

Effectiveness Analysis ◽

Previously Treated ◽

Long Term Survivors

Cost-Effectiveness Analysis of Abiraterone and Sipuleucel-T in Metastatic Castration-Resistant Prostate Cancer

Value in Health ◽

10.1016/j.jval.2014.03.482 ◽

2014 ◽

Vol 17 (3) ◽

pp. A82-A83

Author(s):

C.L. Gong ◽

J.W. Hay

Keyword(s):

Prostate Cancer ◽

Cost Effectiveness ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Will the Addition of Second Generation Anti-Androgens in Addition to Standard Androgen-Deprivation Therapy and Radiotherapy be Cost-Effective in the Treatment of Node Positive Prostate Cancer: A Cost-Effectiveness Analysis

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2019.06.1471 ◽

2019 ◽

Vol 105 (1) ◽

pp. E440

Author(s):

A.A. Konski ◽

R.C. Chen ◽

L. Havrilesky ◽

O. Sartor ◽

J.A. Efstathiou

Keyword(s):

Prostate Cancer ◽

Cost Effectiveness ◽

Second Generation ◽

Cost Effective ◽

Androgen Deprivation ◽

Node Positive ◽

Cost-effectiveness analysis of treatments for metastatic castration resistant prostate cancer

Asian Journal of Urology ◽

10.1016/j.ajur.2016.11.005 ◽

2017 ◽

Vol 4 (1) ◽

pp. 37-43 ◽

Cited By ~ 19

Author(s):

Matthew E. Pollard ◽

Alan J. Moskowitz ◽

Michael A. Diefenbach ◽

Simon J. Hall

Keyword(s):

Prostate Cancer ◽

Cost Effectiveness ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Abstract 2415: Polygenic risk-tailored screening for prostate cancer: A cost-effectiveness analysis

10.1158/1538-7445.am2019-2415 ◽

2019 ◽

Author(s):

Thomas Callender ◽

Mark Emberton ◽

Steve Morris ◽

Ros Eeles ◽

Zsofia Kote-Jarai ◽

...

Keyword(s):

Prostate Cancer ◽

Cost Effectiveness ◽

Polygenic Risk ◽

Abstract 2415: Polygenic risk-tailored screening for prostate cancer: A cost-effectiveness analysis

10.1158/1538-7445.sabcs18-2415 ◽

2019 ◽

Author(s):

Thomas Callender ◽

Mark Emberton ◽

Steve Morris ◽

Ros Eeles ◽

Zsofia Kote-Jarai ◽

...

Keyword(s):

Prostate Cancer ◽

Cost Effectiveness ◽

Polygenic Risk ◽